Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
The University of Basel currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners across 2 distinct art units. This distribution shows that each pending action is being handled by a different individual, though two of the actions share an art unit.
The busiest examiner for the portfolio is PERREIRA, MELISSA JEAN, who is currently managing 1 pending action. Because there are 3 distinct examiners for 3 pending office actions, no single examiner has a dominant influence. Practitioners must navigate the specific requirements of the 2 distinct art units while addressing the individual perspectives of the 3 distinct examiners involved in these cases. The concentration in 2 distinct art units allows for some consistency in the technical narrative across the 3 pending office actions. Success will depend on navigating the individual preferences of the 3 distinct examiners, including PERREIRA, MELISSA JEAN, while maintaining a cohesive strategy that aligns with the expectations of the 2 distinct art units overseeing the work.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERREIRA, MELISSA JEAN | 2 | 52.0% | +25.8% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248124 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18477504 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | PERREIRA, MELISSA JEAN | 30d overdue |
| 19548526 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | PERREIRA, MELISSA JEAN | — |
| 18566029 | METHODS OF TREATING AGE-RELATED FRAILTY WITH INTERLEUKIN-6 | SAOUD, CHRISTINE J | — |
| 18248124 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19548526 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | PERREIRA, MELISSA JEAN | 1618 | §102§103DP | Non-Final OA | — | Pending | Feb 24, 2026 |
| 18566029 | METHODS OF TREATING AGE-RELATED FRAILTY WITH INTERLEUKIN-6 | SAOUD, CHRISTINE J | — | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18477504 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | PERREIRA, MELISSA JEAN | 1618 | §103 | Final Rejection | 30d overdue | Pending | Sep 28, 2023 |
| 18248124 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | LADD, CAROLYN LOUISE | 1622 | §102§103 | Non-Final OA | — | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial